Role of nuclear factor-xB in female breast cancer: A study in indian patients

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 11, 2012, Pages 5511-5515

  Jana, Debarshi ^a   Das, Soumen ^a   Sarkar, Diptendra Kumar ^a   Mandal, Syamsundar ^b   Maji, Abhiram ^c   Mukhopadhyay, Madhumita ^a  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^c CALCUTTA NATIONAL MEDICAL COLLEGE   (India)

Author keywords

Breast cancer; Eastern India; Nottingham Prognostic Index; Nuclear factor XB; Prognostic marker

Indexed keywords

EID: 84874039233     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.11.5511     Document Type: Article

References (35)

1. Almasri NM, Al Hamad M (2005). Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Res, 7, 598-604.
2. Balkwill F, Mantovani A (2001). Inflammation and cancer: back to Virchow?. Lancet, 357, 539-45.
3. Biswas DK, Cruz AP, Gansberger E, Pardee AB (2000). Epidermal growth factor-induced nuclear factor kB activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. PNAS, 97, 8542-47.
4. Biswas DK, Dai S-C, Cruz A, et al (2001). The nuclear factor kappa B (NF-kB): A potential therapeutic target for estrogen receptor negative breast cancers. PNAS, 98, 10386-91.
5. Biswas DK, Martin KJ, McAlister C, et al (2003). Apoptosis Caused by Chemotherapeutic Inhibition of Nuclear Factor-kappaB Activation. Cancer Res, 63, 290-95.
6. Borg A, Tandon AH, Sigurdsson H, et al (1990). HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res, 50, 4332-7.
7. Carter CL, Allen C, Henson D (1989). Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer, 63, 181-7.
8. Chen LF, Greene WC (2004). Shaping the nuclear action of NF-kappaB. Nature Rev, 5, 392-401.
9. Cooke T, Reeves J, Lanigan A, Stanton P (2001). HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol, 12, 23-28.
10. Ferlay J BF, Pisani P, Parkin DM, (2000). Cancer Incidence, Mortality and Prevalence Worldwide. Globocan, Version 1.0.
11. Ferlay J SH, Bray F, Forman D, Mathers C and Parkin DM (2008). Cancer Incidence and Mortality Worldwide. Globocan, Version 1.2
12. Greten FR, Karin M (2004). The IKK/NF-1B activation pathway-a target for prevention. Cancer Letters, 206, 193-99.
13. Gupta SC, Sundaram C, Reuter S, Bharat B (2010). Aggarwal. Inhibiting NF-1B activation by small molecules as a therapeutic strategy. Biochimica et Biophysica Acta, 1799, 775-87.
14. Henson DE, Ries L, Freedman LS, et al (1991). Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. Cancer, 68, 2142-49.
15. Houa M-F, Lin S-B, Yu SS, et al (2003). The clinical significance between activation of nuclear factor kappa B transcription factor and overexpression of HER-2/neu oncoprotein in Taiwanese patients with breast cancer. Clin Chim Acta, 334, 137-144.
16. Jana D, Sarkar DK, Maji A, et al (2012). Can cyclo-oxygenase-2 be a useful prognostic and risk stratification marker in breast cancer. J Indian Med Assoc, 110, 429-33.
17. Merkhofer EC, Cogswell P, Baldwin AS (2010). Her2 activates NF-1B and induces invasion through the canonical pathway involving IKKa. Oncogene, 29, 1238-48.
18. Nakshatri H, Bhat-Nakshatri P, Martin DA, et al (1997). Constitutive activation of NF-kB during progression of breast cancer to hormone-independent growth. Molecul Cell Biol, 17, 3629-39.
19. Yamashita H, Nishio M, Toyama T, et al (2004). Coexistence of HER2 over-expression and p53 protein accumulation is astrong prognostic molecular marker in breast cancer. Breast Cancer Res, 6, 24-30.
20. Kalkhoven E, Wissink S, van der Saag PT, van der Burg B (1996). A role for transcription factor NF-1B in autoimmunity: possible interactions of genes, sex, and the immune response. J Biol Chem , 271, 6217-24.
21. Karin M, Lin A (2002). NF-kappaB at the crossroads of life and death. Nat Immunol, 3, 221-27.
22. Montagut C, Tusquets I, Ferrer B, et al (2006), Activation of nuclear factor-1B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocrine-Related Cancer, 13, 607-16.
23. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr and Sledge GW Jr (1997).Constitutive activation of NFkappaB during progression of breast cancer to hormone-independent growth. Molecular and Cellular Biology, 17, 3629-39.
24. Radhakrishnan SK, Kamalakaran S (2006). Pro-apoptotic role of NF-1B: Implications for cancer therapy. Biochim Biophys Acta, 1766, 53-62.
25. Sarkar DK, Lahiri S, Pandey S (2009). Is estrogen receptor study useful in prognostication of breast cancer patients in India? Indian J Surg Oncol, 1, 37-9.
26. Sen U, Sankaranarayanan R, Mandal S, et al (2002). Cancer patterns in eastern India: The first report of the Kolkata Cancer Registry. Int J Cancer, 100, 86-91.
27. Sethi G, Sung B, and Aggarwal BB (2008). Nuclear Factor-1B activation: From bench to bedside. Exp Biol Med, 233, 21-31.
28. Sethi G, Tergaonkar V (2009). Potential pharmacological control of the NF-kB pathway. Cell, 30, 313-21
29. Taneja P, Maglic D, Kai F, et al (2010). Classical and novel prognostic markers for breast cancer and their clinical significance. Oncology, 4, 15-34.
30. Tovey SM, Brown S, Doughty JC, et al (2009). Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumors. Br J Cancer, 100, 680 - 83.
31. Van Laere SJ, Van der Auwera I, Van den Eynden GG, et al (2007). NF-kB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation. Br J Cancer, 97, 659-69.
32. Wu JT, Kral JG (2005). The NF-1B/I1B signaling system: A molecular target in breast cancer therapy. J Surgical Res, 123, 158-69
33. Wülfing P, Borchard J, Buerger H, et al (2006). HER2-positive circulating tumor cells indicate poor clinical outcome in Stage I to III breast cancer patients. Clin Cancer Res, 12, 1715-20.
34. Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC (2005). The NF-1B pathway and endocrine-resistant breast cancer. Endocrine-Related Cancer, 12, 37-46.
35. Zhou Y, Eppenberger-Castori S, Marx C, et al (2005). Activation of nuclear factor-1B (NF-1B) identifies a high-risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol, 37, 1130-44.